Mode
Text Size
Log in / Sign up
N/A N=25 Treatment

Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal

Peripheral Artery Disease · PAD · Claudication · Peripheral Vascular Disease · PVD

Enrolled (actual)
25
Serious AEs
40.0%
Results posted
Aug 2017
Primary outcome: Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Stealth 360°® OAS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Rate of Clinically Driven Target Lesion Revascularization (TLR)
4.0; 8.2
PRIMARY
Mean Maximum Balloon Inflation Pressure
5.2
PRIMARY
Rate of Procedural Angiographic Complications
0; 0; 0; 4; 0
PRIMARY
Ankle-Brachial Index (ABI) Measurments
0.74; 1.01; 0.96; 0.95
PRIMARY
Rutherford Classification (RC)
0; 24; 19; 13; 0; 1
PRIMARY
Stent Usage at the Time of the Index Procedure
17
PRIMARY
Percent (%) Area Stenosis
76.9; 63.8; 43.0

Summary

IVUS imaging will be utilized to assess performance of the Sponsor's Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA) in patients who have symptomatic peripheral artery disease (PAD) occurring in the Superficial Femoral Artery (SFA), Popliteal (POP), and/or Tibioperoneal Trunk (TPT).

Eligibility Criteria

Inclusion Criteria

  • Subject's age ≥ 18 years
  • Subject is an acceptable candidate for percutaneous intervention using the Sponsor's OAS in accordance with its labeled indications and instructions for use
  • Target lesion(s) located in a superficial femoral artery (SFA), popliteal (POP) or tibioperoneal trunk (TPT)
  • Tight lesions (>70% stenosis)
  • Lesions less than 110 mm in length
  • Artery with the vessel 2.5 mg/dl) at the time of treatment
  • Female subject who is pregnant or nursing a child
  • Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Sponsor's OAS
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01938391). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search